The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, ...

Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

For the second time in under 3 weeks, the FDA has approved treatment for the inherited genetic disorder characterized by ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

The attack data in RAPIDe-3 have continued to accrue following the achievement of target enrollment in the study; we now estimate that our RAPIDe-3 topline data announcement will be in the fourth ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...

BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary ...